TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
Researchers from University of Khartoum detail findings in leishmaniasis
March 18th, 2008
"Post-kala-azar dermal leishmaniasis (PKDL) is a recognized dermatosis that follows successful treatment of visceral leishmaniasis in the Sudan. This randomized and double-blind study aimed to assess safety, immunogenicity and curative potentials of a novel immunochemotherapy regimen in patients with persistent PKDL," scientists in Khartoum, Sudan report. "Following informed consent, 30 patients were randomized to receive alum-precipitated autoclaved Leishmania major (Alum/ALM) vaccine + Bacille Calmette-Guerin (BCG) and sodium stibogluconate (SSG) or vaccine diluent and SSG. The SSG +Alum/ALM+BCG proved safe with minimal. local adverse events. In the SSG+vaccine group,...
Source: TB & Outbreaks Week (2008-03-18)
|
